Search Results

Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott’s world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

Abbott will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

The board of directors of Abbott declared a quarterly common dividend of 55 cents per share.

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).

Auburn Community Hospital is the first institution in the United States to integrate Abbott’s Alinity h‐series into the ACH Core Laboratory.